Monge et al., Immunovirological response to cART in migrants
Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?  HIV Medicine Monge et al. on behalf of COHERE in EuroCoord aimed to evaluate differences in immunovirological response to combination antiretroviral therapy (cART) in migrant and native men and women. Of 32’817 individuals, […]
Elzi et al., Effetti avversi degli inibitori dell’integrasi dolutegravir e raltegravir
Effetti avversi degli inibitori dell’integrasi dolutegravir e raltegravir.  AIDS Le raccomandazioni internazionali consigliano come terapia iniziale per le persone con HIV una combinazione con inibitore dell’integrasi. Dolutegravir e raltegravir sono gli inibitori dell’integrasi prescritti più frequentemente grazie alla loro efficacia e buona tolleranza. Negli ultimi due anni, differenti studi hanno riportato degli effetti avversi […]
Elzi et al., Nebenwirkungen auf die Integrase-Hemmer Dolutegravir und Raltegravir
Nebenwirkungen auf die Integrase-Hemmer Dolutegravir und Raltegravir.   AIDS Internationale Guidelines empfehlen heutzutage als Ersttherapie für HIV-infizierte Personen den Beginn eines Integrase-Hemmers. Zu den am häufigsten verschriebenen Integrase-Hemmern gehören die Substanzen Dolutegravir und Raltegravir aufgrund ihrer hohen Wirksamkeit und guten Verträglichkeit. In den letzten zwei Jahren wurden vermehrt Studien publiziert, welche von einer erhöhten Nebenwirkungsrate […]
Elzi et al., Effets secondaires des inhibiteurs de l’intégrase Dolutegravir et Raltegravir
Effets secondaires des inhibiteurs de l’intégrase Dolutegravir et Raltegravir.   AIDS Les directives internationales conseillent comme première thérapie pour les personnes atteintes du VIH un inhibiteur de l’intégrase. Dolutegravir et Raltegravir sont les inhibiteurs de l’intégrase le plus fréquemment prescrits grâce à leur grande efficacité et leur bonne tolérance. Ces deux dernières années, différentes études […]
Boyd et al., Combined CVD and CKD risk in the D:A:D study
Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. Â PLoS Medicine The D:A:D study has developed specific models to predict the risk for CVD and CKD events in HIV-positive people. Boyd et al. on behalf […]
Wittkop et al., CD4 cell count response to first-line cART in HIV-2+ versus HIV-1+ patients
CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Â Journal of Antimicrobial Chemotherapy Wittkop et al. on behalf of the COHERE in EuroCoord and the ACHIeV2e Study Group aimed to assess CD4 cell recovery following first-line combination ART (cART) in HIV-2+ infected individuals […]
Veit et al., Yellow fever vaccine in HIV-infected individuals
Long-term immune response to yellow fever vaccination in HIV-infected individuals depends on HIV-RNA suppression status: Implications for vaccination schedule. Â Â Clinical Infectious Diseases Veit et al. studied the immune response over time to yellow fever vaccination (YFV) and the necessity for booster vaccination in 247 HIV-infected individuals from the Swiss HIV Cohort Study. A plaque […]
Thorne et al., Coinfection with HIV and HCV in children and young adults living in Europe
Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe. Â Â AIDS Thorne et al. on behalf of EuroCoord aimed to conduct a study of HIV/hepatitis C virus (HCV) coinfection in children, adolescents and young adults infected with HIV/HCV vertically or before age 18 years to characterize this […]
Ryom et al., eGFR after chronic renal impairment
Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals.   AIDS Ryom et al. on behalf of the D:A:D study group aimed to investigate the improvement in estimated glomerular filtration rate (eGFR) after development of chronic renal impairment (CRI) in HIV-positive individuals. The median of all eGFRs measured 24–36 months after […]
Rhee et al., Mutational correlates of virological failure in individuals receiving WHO-recommended tenofovir-containing regimen
Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: an international collaboration. Â Â EBioMedicine Tenofovir disoproxil fumarate (TDF) genotypic resistance defined by K65R/N and/or K70E/Q/G occurs in 20% to 60% of individuals with virological failure on a WHO-recommended TDF-containing first-line regimen. Rhee et al. aimed to identify TDF regimen-associated mutations (TRAMs) […]